Metabolism of alpha-phosphonosulfonate squalene synthase inhibitors. I. Disposition of a farnesylethyl alpha-phosphonosulfonate and ester prodrugs in rats.
The disposition of I [(E,E)-6,10,14-trimethyl-1-phosphono-5,9, 13-pentadecatriene-1-sulfonic acid] and its mono- (II), di- (III), and triester (IV) prodrugs in rats was studied with 14C-labeled compounds. After iv administration of I (15 micromol/kg), radioactivity in plasma was measurable up to 96 hr and averaged 0. 026 microg-eq/ml. I accounted for >50% of the radioactivity in plasma and had an apparent half-life of 4 hr. After oral administration of the same dose, the maximal plasma concentration of radioactivity averaged 0.108 microg-eq/ml at 6 hr. In 96 hr, 19 and 73% of the iv dose and 2 and 97% of the po dose was excreted in urine and feces, respectively. The absorption was 2.4%, based on the plasma data. In 12 hr after an iv dose of I to bile duct-cannulated rats, 41 and 14% of the dose was excreted in bile and urine, respectively. I accounted for 51% of the radioactivity in bile and a negligible amount in urine. At 12 hr after iv dosing, liver retained 31% of the dose. No accumulation of radioactivity in bone was observed. I (3%) and II (6%) were poorly absorbed. Enhanced absorption was observed for III (80%) and IV (45%). No I or metabolites of I were found in bile or urine of rats dosed with the prodrugs. The structures of two metabolites each for I, III, and IV were proposed. Together, they accounted for >80% of the radioactivity in urine and approximately 50% of the radioactivity in bile for each compound. Metabolism appeared to occur primarily at the farnesyl moiety, presumably by the same pathways as for farnesyl-1-pyrophosphate.
Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543, USA.
S J
SJ
Lan
D C
DC
Hsieh
J W
JW
Hillyer
R M
RM
Fancher
K J
KJ
Rinehart
B M
BM
Warrack
R E
RE
White
D000818:Animals; D001646:Bile / Q000378:metabolism; D001711:Biotransformation; D002250:Carbon Radioisotopes / Q000493:pharmacokinetics; D002851:Chromatography, High Pressure Liquid; D004791:Enzyme Inhibitors / Q000378:metabolism / Q000493:pharmacokinetics* / Q000652:urine; D004952:Esters; D013186:Farnesyl-Diphosphate Farnesyltransferase / Q000037:antagonists & inhibitors*; D008297:Male; D013058:Mass Spectrometry; D010088:Oxidoreductases / Q000037:antagonists & inhibitors*; D011355:Prodrugs / Q000378:metabolism / Q000493:pharmacokinetics*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013451:Sulfonic Acids / Q000493:pharmacokinetics*
C115397:BMS 183743; D002250:Carbon Radioisotopes; D004791:Enzyme Inhibitors; D004952:Esters; D011355:Prodrugs; D013451:Sulfonic Acids; D010088:Oxidoreductases; D013186:Farnesyl-Diphosphate Farnesyltransferase